A widely-used diabetes drug should be pulled from the market, European regulators say.Avandia is used to control blood sugar levels in type 2 diabetes patients. It was licensed 10 years ago and more than 100,000 patients in the UK use it despite on-going concerns linking it to heart problems. After reviewing safety data, the European Medicines Agency said the benefits no longer outweighed the risks and it should be suspended. The drug - generic name rosiglitazone - is also used in combination with other drugs under the names Avandamet and Avaglim.